Shipping to United States We Offer Worldwide Shipping
Login Wishlist

Denudatin B


  • Brand : BIOFRON

  • Catalogue Number : BD-P0537

  • Specification : 98.0%(HPLC)

  • CAS number : 87402-88-8

  • Formula : C21H24O5

  • Molecular Weight : 356.41

  • PUBCHEM ID : 442834

  • Volume : 50mg

Available on backorder

Checkout Bulk Order?

Catalogue Number


Analysis Method






Molecular Weight




Botanical Source

Structure Type



Standards;Natural Pytochemical;API




(2S,3R,3aR)-5-Allyl-2-(3,4-dimethoxyphenyl)-3a-methoxy-3-methyl-3,3a-dihydro-1-benzofuran-6(2H)-one/Denudatin B/6(2H)-Benzofuranone, 2-(3,4-dimethoxyphenyl)-3,3a-dihydro-3a-methoxy-3-methyl-5-(2-propen-1-yl)-, (2S,3R,3aR)-





1.2±0.1 g/cm3


Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

214.2±28.8 °C

Boiling Point

491.1±45.0 °C at 760 mmHg

Melting Point



InChl Key


WGK Germany


HS Code Reference


Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:87402-88-8) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.




Six amides, piperbonamides A-F, three neolignans piperbonins A-C, and 11 known compounds were isolated from the aerial parts of Piper bonii (Piperaceae). The structures of piperbonamides A-F and piperbonins A-C were elucidated based on the analysis of 1D and 2D NMR and MS data. Piperbonin A, (+)-trans-acuminatin, (+)-cis-acuminatin, (+)-kadsurenone, and pipernonaline showed weak activity against platelet aggregation with IC50 values of 118.2, 108.5, 90.02, 107.3, and 116.3 μM, respectively, as compared with the positive control, tirofiban, with an IC50 value of 5.24 μM. Piperbonamides A-F were inactive against five tumor cell lines at concentrations up to 40 μM.

Copyright © 2016. Published by Elsevier Ltd.


Amides; Antiplatelet; Neolignans; Piper bonii; Piperaceae


Amides and neolignans from the aerial parts of Piper bonii.


Ding DD1, Wang YH1, Chen YH2, Mei RQ1, Yang J1, Luo JF1, Li Y3, Long CL4, Kong Y5.

Publish date

2016 Sep




A sensitive and rapid LC-MS/MS method was developed and validated for the determination of kadsurenone in rat plasma using lysionotin as the internal standard (IS). The analytes were extracted from rat plasma with acetonitrile and separated on a SB-C18 column (50 × 2.1 mm, i.d.; 1.8 µm) at 30 °C. Elution was achieved with a mobile phase consisting of methanol-water-formic acid (65:35:0.1, v/v/v) at a flow rate of 0.30 mL/min. Detection and quantification for analytes were performed by mass spectrometry in the multiple reaction monitoring mode with positive electrospray ionization m/z at 357.1 → 178.1 for kadsurenone, and m/z 345.1 → 315.1 for IS. Calibration curves were linear over a concentration range of 4.88-1464 ng/mL with a lower limit of quantification of 4.88 ng/mL. The intra- and inter-day accuracies and precisions were <8.9%. The LC-MS/MS assay was successfully applied for oral pharmacokinetic evaluation of kadsurenone using the rat as an animal model. Copyright © 2013 John Wiley & Sons, Ltd.


Alzheimer's disease; Piper kadsura; kadsurenone; pharmacokinetic; rat plasma


Development of an LC-MS/MS method for quantification of kadsurenone in rat plasma and its application to a pharmacokinetic study.


Zhang N1, Li R, Yu H, Shi D, Dong N, Zhang S, Wang H.

Publish date

2013 Dec;




Kadsurenone is a neolignan with specific antagonistic activity of platelet-activating factor, and is derived from the stems of Piper kadsura. To investigate the mechanism of hepatobiliary excretion of kadsurenone and its association with P-glycoprotein (P-gp), and to explore whether the hepatobiliary excretion of kadsurenone was associated with P-gp, a microdialysis system coupled with HPLC was developed to measure free-form kadsurenone in rat blood and bile. This study design was parallel in the following groups: six rats received kadsurenone alone (20 and 30 mg/kg, i.v.) as control group and the treated-group rats were co-administered with kadsurenone and CsA; P-gp inhibitor. The microdialysis probes were respectively inserted into the jugular vein toward right atrium and bile duct of male Sprague-Dawley rats for blood and bile sampling. CsA (20mg/kg) was administered 10 min prior to kadsurenone administration through the femoral vein and the collected samples were analyzed by a HPLC system. The analytes were separated by a C18 column (150 x 4.6 mm I.D., 5 microm) with a mobile phase of acetonitrile-water (50:50, v/v) at a flow-rate of 1 mL/min. The UV detection wavelength was set 235 nm. The calibration curve was linear over the concentration range of 0.05-10 microg/mL with the coefficient of determination of 0.997. The inter- and intra-assay accuracy and precision of the method ranged from -9.53% to 6.75%. The limit of detection and the limit of quantification were 0.01 and 0.05 microg/mL, respectively. The hepatobiliary excretion ratio of kadsurenone was defined by dividing the values of the area under the drug concentration curve (AUC) for bile and blood (AUC(bile)/AUC(blood)). The results indicated that the hepatobiliary excretion ratio of kadsurenone on the CsA treated-group was 1.2+/-0.1, which was not significantly different from the group of kadsurenone alone (1.3+/-0.2). This fact indicates that kadsurenone went through hepatobiliary excretion but might not be regulated by P-gp.


Pharmacokinetics of kadsurenone and its interaction with cyclosporin A in rats using a combined HPLC and microdialysis system.


Huang SP1, Lin LC, Wu YT, Tsai TH.

Publish date

2009 Jan 15